ITP Education Kit

Learn more about ITP and WinRho when you order the ITP Educational Resource Kit
educational patient kit

ITP Juego Educativo

Aprenda más acercade ITP
y WinRho cuando usted ordena el ITP Juego Educativo de Recurso

Efficacy *

WinRho® SDF [Rho(D) Immune Globulin Intravenous (Human)] is effective in increasing platelet levels in Rh-positive patients. 1,2

* Study was performed using WinRho/WinRho SD
† Dose = 20-75 µg/kg (100-375 IU/kg); Response - Platelet increase to ≥ 20,000/mm3
‡ Dose = 25-55 µg/kg (125-275 IU/kg); Response = platelet increase to ≥ 50,000/mm3 and doubling of baseline platelet count

WinRho SDF Liquid is Bioequivalent to WinRho SDF Lyophilized

In two comparative pharmacokinetic studies (n=101), the formulations were bioequivalent following IV administration based on area under the curve to 84 days and had comparable pharmacokinetics following IM administration. Both formulations also had similiar elimination half-lives. WinRho®  SDF must be administered via the intravenous route for the treatment of ITP.

*Study was performed using WinRho/WinRho SD
† 25µg/kg (125 IU/kg) for 2 days

Please see Important Safety Information and Prescribing Information.

  1. WinRho® SDF [Rho(D) Immune Globulin Intravenous (Human)] package insert, Cangene Corporation,Winnipeg, Canada. Baxter Healthcare Corporation,WestlakeVillage, CA, USA, April 2006.
  2. Data on file, Cangene Corporation, Baxter Healthcare Corporation.